Showing results (1741-1750 of 6,517) with videos related to
Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|June 13, 2006
Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and ApoptinHai Lian, Ningyi Jin, Xiao Li, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1991
Number of helper T cells and phytohemagglutinin stimulation correlate in cancer patientsJ Richner, E P Ambinder, K Hoffmann, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1991
Effect of a glucan, sizofiran, on natural-killer activity of 5-fluorouracil-treated murine bone marrow cellsY Tsuchiya, M Matsutani, M Inoue, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1991
Human lymphokine-activated killer (LAK) cells: III. Effect of L-phenylalanine methyl ester on LAK cell activation from human peripheral blood mononuclear cells: possible protease involvement of monocytes, natural killer cells and LAK cellsK H LeungCancer Immunology, Immunotherapy : CII|May 25, 2007
Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancerLisa H Butterfield, Antoni Ribas, Douglas M Potter, et al.Cancer Immunology, Immunotherapy : CII|May 25, 2007
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapyJustin T Jordan, Wei Sun, S Farzana Hussain, et al.Cancer Immunology, Immunotherapy : CII|February 1, 2007
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicityStephen R Mattarollo, Tony Kenna, Mie Nieda, et al.Cancer Immunology, Immunotherapy : CII|January 16, 2007
An MVA vaccine overcomes tolerance to human p53 in mice and humansGuang-Yun Song, Glen Gibson, Wahajul Haq, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1991
In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chainO Rostaing-Capaillon, P CasellasCancer Immunology, Immunotherapy : CII|December 2, 2006
Small numbers of residual tumor cells at the site of primary inoculation are critical for anti-tumor immunity following challenge at a secondary locationTakashi Kakinuma, Hari Nadiminti, Anke S Lonsdorf, et al.Pageof 652